The Subtype of GluN2 C-terminal Domain Determines the Response to Excitotoxic Insults

Marc-André Martel,1 Tomás J. Ryan,2,3,6 Karen F.S. Bell,1,6 Jill H. Fowler,4,6 Aoife McMahon,1 Bashayer Al-Mubarak,1 Noboru H. Komiyama,5 Karen Horsburgh,4 Peter C. Kind,1 Seth G.N. Grant,5,6 David J.A. Wyllie,1 and Giles E. Hardingham1,*

1Centre for Integrative Physiology, University of Edinburgh School of Biomedical Sciences, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK
2Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
3Wolfson College, University of Cambridge, Barton Road, Cambridge CB3 9BB, UK
4Centre for Neuroregeneration, University of Edinburgh Chancellor’s Building, Edinburgh EH16 4SB, UK
5Centre for Clinical Brain Sciences and Centre for Neuroregeneration, University of Edinburgh Chancellor’s Building, Edinburgh, EH16 4SB, UK
6These authors contributed equally to this work
*Correspondence: seth.grant@ed.ac.uk (S.G.N.G.), giles.hardingham@ed.ac.uk (G.E.H.)
DOI 10.1016/j.neuron.2012.03.021

SUMMARY

It is currently unclear whether the GluN2 subtype influences NMDA receptor (NMDAR) excitotoxicity. We report that the toxicity of NMDAR-mediated Ca2+ influx is differentially controlled by the cytoplasmic C-terminal domains of GluN2B (CTD 2B) and GluN2A (CTD 2A). Studying the effects of acute expression of GluN2A/2B-based chimeric subunits with reciprocal exchanges of their CTDs revealed that CTD 2B enhances NMDAR toxicity, compared to CTD 2A. Furthermore, the vulnerability of forebrain neurons in vitro and in vivo to NMDAR-dependent Ca2+ influx is lowered by replacing the CTD of GluN2B with that of GluN2A by targeted exon exchange in a mouse knockin model. Mechanistically, CTD 2B exhibits stronger physical/functional coupling to the PSD-95-nNOS pathway, which suppresses protective CREB activation. Dependence of NMDAR excitotoxicity on the GluN2 CTD subtype can be overcome by inducing high levels of NMDAR activity. Thus, the identity (2A versus 2B) of the GluN2 CTD controls the toxicity dose-response to episodes of NMDAR activity.

INTRODUCTION

Sustained elevated levels of extracellular glutamate kill central neurons (Olney, 1969). This “excitotoxicity” is implicated in neuronal loss in acute neurological disorders, including stroke, traumatic brain injury, and chronic disorders including Huntington’s disease (Berliocchi et al., 2005; Choi, 1988; Fan and Raymond, 2007; Lau and Tymianski, 2010). A major cause of glutamate excitotoxicity is inappropriate activity of the NMDA subtype of glutamate receptor (NMDAR), which mediates Ca2+-dependent cell death (Choi, 1992; Lipton, 2006). Most NMDARs contain two obligate GluN1 subunits plus two GluN2 subunits (Furukawa et al., 2005), of which there are four subtypes, GluN2A-D, with GluN2A and GluN2B predominant in the forebrain (Cull-Candy et al., 2001; Monyer et al., 1994; Paoletti, 2011; Traynelis et al., 2010). GluN2 subunits have large, evolutionarily divergent cytoplasmic C-terminal domains (CTDs), which have the potential to differentially associate with signaling molecules (Ryan et al., 2008). This compositional diversity raises the (unresolved) question as to whether the GluN2 subtype (GluN2A versus GluN2B) differentially influences the toxicity of Ca2+ influx through NMDARs. There is evidence that GluN2B- and GluN2A-containing NMDARs are both capable of mediating excitotoxicity (Graham et al., 1992; Lau and Tymianski, 2010; von Engelhardt et al., 2007); however, whether they do so with differing efficiency or mechanisms is unclear.

In answering questions relating to subunit-specific function (including excitotoxicity), it is becoming clear that pharmacological approaches are of limited use, given the tools currently available (Neyton and Paoletti, 2006). Although GluN2B-specific antagonists are highly selective and have demonstrated a role for GluN2B-containing NMDARs in excitotoxicity (Liu et al., 2007), attempts to study the role of GluN2A (Liu et al., 2007) employed a mildly selective GluN2A-prefering antagonist (NVP-AAM007) at a concentration shown by others to antagonize GluN2B-containing NMDARs (Berberich et al., 2005; Frizelle et al., 2006; Martel et al., 2009; Neyton and Paoletti, 2006; Weitlauf et al., 2005), rendering some of the findings hard to interpret. Moreover, the less-controllable conditions in an intact brain render a weakly selective competitive antagonist, such as NVP-AAM007, of limited value for in vivo studies. Another important issue is that receptors can exist in a triheteromeric form that contains both a GluN2A and a GluN2B subunit (Hatton and Paoletti, 2005; Rauner and Körh, 2011), where the role of each subunit cannot be established using currently available pharmacological tools.

Additional problems in relating function to GluN2 subunit composition include their different spatiotemporal expression profiles. For example, in younger neurons, GluN2B is predominant and as such may mediate excitotoxicity simply because...
most NMDARs are GluN2B-containing. Moreover, GluN2B- and GluN2A-containing NMDARs may be enriched at extrasynaptic and synaptic sites, respectively (Groc et al., 2008; Martel et al., 2009; Tovar and Westbrook, 1999, but see Harris and Pettit, 2007; Thomas et al., 2006). Since receptor location may be a determinant of excitotoxicity irrespective of subunit composition (Hardingham and Bading, 2010), a location-dependent effect may be misinterpreted as a subunit-specific effect.

We have eschewed pharmacocentric approaches in favor of molecular genetics to determine whether equivalent levels of Ca$^{2+}$ influx through GluN2A- and GluN2B-containing NMDARs differentially affect neuronal viability. We hypothesized that any differences would be due to their large CTDs because this is the primary area of sequence divergence, as well as being the part of GluN2 known to bind intracellular signaling/scaffolding proteins (Ryan et al., 2008). By studying signaling from wild-type and chimeric GluN2A/2B subunits, using both acutely expressed subunits as well as a mouse knockin model, we find that the presence of the CTD$^{2B}$ in an NMDAR renders Ca$^{2+}$ influx through this receptor more toxic than the presence of CTD$^{2A}$. This difference is observed in vivo as well as in vitro and is attributable in part to enhanced physical/functional coupling of CTD$^{2B}$ to the PSD-95/nNOS signaling cassette, which suppresses pro-survival CREB-mediated gene expression, rendering neurons vulnerable to excitotoxic cell death.

RESULTS

The CTDs of GluN2B and GluN2A Differentially Influence Excitotoxicity Independent of the Identity of the Rest of the Subunit

We wanted to investigate whether the subtype of GluN2 CTD influences the excitotoxicity of a given amount of NMDAR-mediated ion flux. We created constructs encoding chimeric receptors based on GluN2B and GluN2A but with their respective CTDs replaced (denoted as CTR) with each other’s (GluN2B-$^{2ACTR}$ and GluN2A-$^{2BCTR}$, respectively, Figure 1A). In rat hippocampal neurons, we first expressed either wild-type GluN2BWT or GluN2B-$^{2ACTR}$, at a developmental stage where endogenous NMDARs are overwhelmingly GluN2B-containing (Martel et al., 2009). Expression of GluN2B WT or GluN2B-$^{2ACTR}$ both enhanced whole-cell currents to a similar level (Figure 1B) and did not differentially affect the proportion of extrasynaptic NMDARs (Figure 1C), as assessed by the “quantal block” method of irreversibly blocking synthetically located NMDARs (Papadia et al., 2008). Thus, any differential CTD-specific effects on excitotoxicity can be studied without the complicating factor of altered NMDAR location, which itself influences survival/death signaling via mechanisms that are likely to be independent of GluN2 subtype (Hardingham and Bading, 2010; Martel et al., 2009; Papadia et al., 2008).

We next studied whether expression of GluN2B WT or GluN2B-$^{2ACTR}$ had different effects on vulnerability to excitotoxicity. NMDA (20 μM) was applied for 1 hr to neurons transfected with vectors encoding either GluN2B WT, GluN2B-$^{2ACTR}$ or control vector, and neuronal death was assessed 24 hr later. GluN2B WT strongly increased the level of cell death compared to the control, consistent with NMDAR currents being higher (Figures 1D and 1E). However, expression of GluN2B-$^{2ACTR}$ caused a significantly lower enhancement of cell death than GluN2B WT (Figures 1D and 1E), despite NMDAR currents being equal (Figure 1B), suggesting that CTD$^{2B}$ promotes cell death better than CTD$^{2A}$. The same result was found when the experiment was repeated in DIV18 neurons (see Figure S1A available online), indicating that the differential effect of CTD$^{2B}$ versus CTD$^{2A}$ on cell death also holds true in more mature neurons.

To further investigate the differential CTD subtype effects on excitotoxicity, we compared NDMA-dependent cell death in neurons expressing GluN2A WT and GluN2A-$^{2BCTR}$. Expression of GluN2A WT and GluN2A-$^{2BCTR}$ did not differentially affect the proportion of extrasynaptic NMDARs (Figure 1C) and caused similar increases in NMDAR currents (Figure 1F); although, because of the lower affinity of GluN2A for NDMA, the increases were smaller than for the GluN2B-based constructs (Figure 1B). We found that neurons expressing GluN2A-$^{2BCTR}$ were significantly more vulnerable to NDMA-induced excitotoxicity than GluN2A WT-expressing neurons (Figure 1G). Thus, for a given amount of NMDAR-mediated current, the presence of CTD$^{2B}$...
promotes neuronal death better than CTD2A, regardless of whether they are linked to the channel portion of GluN2A or GluN2B. This result illustrates the independent influence of the identity of the CTD on excitotoxicity, acting in addition to the influence of the identity of the rest of the channel on downstream signaling events (e.g., because of different channel kinetics and ligand binding properties).

A Mouse Knockin Model Reveals the Influence of the GluN2 CTD Subtype In Vitro and In Vivo

We next investigated the importance of the GluN2 CTD subtype by an independent approach: a genetically modified “knockin” mouse in which the protein coding portion of the C-terminal exon of GluN2B (encoding over 95% of the CTD) was exchanged for that of GluN2A (GluN2B2ACTR; Figure 2A; see Supplemental Experimental Procedures). The 3’UTR of GluN2B, which also forms part of the C-terminal exon, was unchanged apart from a 61 bp insertion at its beginning (a remnant of the excision of a neomycin resistance selection cassette). We wanted to determine whether equivalent Ca2+ influx through GluN2B-containing and GluN2B2ACTR-containing NMDARs would result in different levels of neuronal death. We studied DIV10 cultured cortical neurons from GluN2B+/+ and GluN2B2ACTR/2ACTR littermates. These cultures exhibited similar levels of basal viability and levels of synaptic connectivity and strength, as measured by mini EPSC frequency/size, spontaneous EPSC frequency, and AMPA receptor currents (Figures S2A–S2D), as well as unaltered cell capacitance (Figure S2E).

Whole-cell and extrasynaptic NMDAR currents in both GluN2B+/+ and GluN2B2ACTR/2ACTR neurons were found to be similarly sensitive to the GluN2B-specific antagonist ifenprodil. In neurons of both genotypes, we observed a blockade of around 60% (Figure 2B), indicative of a high (~80%) level of GluN1/GluN2B heterodimeric receptors. Moreover, the proportion of extrasynaptic NMDARs was found to be the same for GluN2B2ACTR/2ACTR neurons (Figure 2C). Thus, any differential CTD subtype-specific effects on excitotoxicity could be studied without the potentially confounding factor of altered NMDAR location. We also investigated whether any differences in use-dependent run-down of whole-cell NMDAR currents were observed because this may be relevant to long-term exposure to NMDA. Having measured baseline whole-cell NMDAR currents, ten further 10 s applications of NMDA were applied over a 10 min period. We found no difference in rundown of steady-state NMDAR currents in GluN2B+/+ and GluN2B2ACTR/2ACTR neurons (around 3% per application; Figure S2F). We also examined NMDAR single-channel properties. We excised outside-out patches from DIV9 GluN2B+/+ and GluN2B2ACTR/2ACTR neurons and measured NMDA-evoked unitary currents, finding no difference in their mean single-channel conductance of approximately 50 pS, which is typical for GluN2B-containing NMDARs (Figure S2G).

Despite the aforementioned similarities, we found one important difference; whole-cell NMDAR currents in GluN2B2ACTR/2ACTR neurons were around 30% lower than GluN2B+/+ (Figure 2D). Levels of GluN2B protein were lower in DIV10 GluN2B2ACTR/2ACTR cortical neurons (Figure S2H) and in P7 cortical protein extracts (Figure S2I; ruling out the possibility of an in vitro artifact). An explanation for this difference was found when we looked at GluN2B2ACTR mRNA levels, which were lower both in DIV10 GluN2B2ACTR/2ACTR cortical neurons and in P7 cortical extracts (Figures S2H and S2I). However,
this decrement appeared to be a developmental-stage-dependent effect because by adulthood, levels of forebrain GluN2B mRNA (Figure 3A) and protein (p = 0.51, n = 5,5) were unaltered in GluN2B+/+ versus GluN2B2A(CTR)/2A(CTR) mice. We hypothesize that GluN2B2A(CTR), compared to wild-type GluN2B, may be transcribed, processed, or exported slightly less efficiently, which
manifests itself in a mRNA decrement in development when expression of many genes, including those encoding NMDA subunits, is changing rapidly.

To compare the effects of equivalent NMDAR activity in GluN2B(CTR)/2A(CTR) and GluN2B+/− neurons, we needed to adjust the concentration of applied NMDA to compensate for the lower currents in GluN2B(CTR)/2A(CTR) neurons. A NMDA dose-response curve for both GluN2B(CTR)/2A(CTR) and GluN2B+/− neurons revealed no difference in their EC−50 s (Figure S2J). Based on these NMDA dose-responses, we predicted that an application of 17 and 21 μM NMDA to GluN2B+/− neurons would induce the same current as an application of 30 and 50 μM, respectively, to GluN2B(CTR)/2A(CTR) neurons (Figure 2E).

This was then confirmed experimentally; application of 17 and 30 μM NMDA (hereafter NMDA C1) applied to GluN2B+/− neurons and GluN2B(CTR)/2A(CTR) neurons, respectively, induced equivalent currents (Figure 2F), as did application of the higher pair of NMDA concentrations: 21 and 50 μM NMDA (hereafter NMDA C2) applied to GluN2B+/− neurons and GluN2B(CTR)/2A(CTR), respectively (Figure 2G). Given that NMDAR-dependent excitotoxicity is predominantly Ca2+-dependent, we next studied the intracellular Ca2+ elevation triggered by NMDA C1 and NMDA C2. Treatment with NMDA C1 caused similar Ca2+ loads in GluN2B(CTR)/2A(CTR) and GluN2B+/− neurons, as did NMDA C2 (Figure 2G).

Satisfied that these doses of NMDA elicit equivalent NMDAR-dependent currents and Ca2+ loads, we next studied their effects on neuronal viability. Strikingly, we found that NMDA C1 and NMDA C2 both promoted more death in GluN2B+/− neurons than in GluN2B(CTR)/2A(CTR) (Figures 2H and 2I). Thus, swapping the GluN2B CTD for that of GluN2A in the mouse genome reduces the toxicity of NMDAR-dependent Ca2+ influx. This is in agreement with our studies based on the overexpression of GluN2A/2B-based wild-type and chimeric subunits (Figure 1), thus confirming the importance of the CTD subtype by two independent approaches. We also performed a similar set of experiments in DIV18 neurons. Because there remained a difference in whole-cell currents (around 25%), we again generated NMDAR current dose-response curves to allow us to pick pairs of NMDA concentrations (15 and 20 μM; 30 and 40 μM) which would trigger equivalent currents (Figure S2K). Consistent with our observations at DIV10, we once again saw increased NMDA-induced death in GluN2B+/− neurons compared to GluN2B(CTR)/2A(CTR) neurons experiencing equivalent levels of NMDAR activity (Figure S2L).

We next wanted to determine whether maximal levels of neuronal death could be achieved in neuronal populations devoid of CTD if NMDAR activity were high enough. We treated GluN2B(CTR)/2A(CTR) neurons with a high dose (100 μM) of NMDA and found that this triggered near-100% neuronal death, as it also did in GluN2B+/− neurons (Figures 2H and 2I). Thus, the influence of excitotoxicity on the GluN2 CTD subtype is abolished when insults are very strong.

In the adult mouse forebrain, GluN2B and GluN2A are the major GluN2 NMDA subunits (Rauner and Köhr, 2011; Sheng et al., 1994), raising the question as to whether the GluN2 CTD subtype (2A versus 2B) influences excitotoxicity in the adult forebrain in vivo. As stated above, adult forebrain GluN2B (protein and mRNA) levels are unaltered in GluN2B+/− versus GluN2B(CTR)/2A(CTR) mice (Figure 3A). We also specifically studied GluN2B levels in isolated protein fractions enriched in synaptic and peri/extrasynaptic NMDARs, following an established protocol (Milnerwood et al., 2010). Briefly, a synaptic preparation was made from the hippocampi of adult GluN2B+/− and GluN2B(CTR)/2A(CTR) mice. This prep was then split into a Triton-soluble “non-PSD enriched” fraction including extrasynaptic NMDARs, plus a Triton-insoluble (but SDS-soluble) “PSD-enriched” fraction containing synaptic NMDARs. We found no differences in the levels of GluN2B between GluN2B+/− and GluN2B(CTR)/2A(CTR) hippocampi with regard to either total homogenate, “Non-PSD enriched” fraction, or “PSD-enriched” fraction (Figure 3B). This biochemical data is in agreement with observations that the NMDAR:AMPAR current ratios in evoked EPSCs measured at holding potentials of −80 and +40 mV are not altered in adult CA1 pyramidal cells of GluN2B(CTR)/2A(CTR) mutants compared to GluN2B+/− controls (Thomas O’Dell, personal communication). Moreover, the decay time constant of NMDAR-mediated EPSCs recorded at +40 mV in GluN2B(CTR)/2A(CTR) mutants was found to be indistinguishable from GluN2B+/− controls (Thomas O’Dell, personal communication), indicative of a similar GluN2 subunit composition.

To promote excitotoxic neuronal loss, we stereotaxically injected a small (15 nmol) dose of NMDA into the hippocampus (just below the dorsal region of the CA1 layer) and quantified the resulting lesion volume 24 hr later. Consistent with the position of the injection site, the lesions were centered on the CA1 subregion, an effect potentially enhanced by the known vulnerability of this subregion to excitotoxic insults (Stanika et al., 2010). However the lesion also spread to other hippocampal subregions (CA3, dentate gyrus) as well as a small intrusion into the thalamus. Importantly, analysis revealed that GluN2B(CTR)/2A(CTR) mice exhibited smaller lesion volumes in the hippocampus and the thalamic region (and smaller overall lesion volumes) than GluN2B+/− mice (Figures 3C–3F). Thus, the GluN2 CTD subtype also influences NMDAR-mediated excitotoxicity in vivo.

**Differential Signaling to CREB Contributes to GluN2 CTD Subtype-Specific Excitotoxicity**

We next investigated the mechanistic basis for the observed GluN2 CTD subtype-dependent differences in vulnerability to excitotoxicity. NMDAR-dependent activation of CREB-dependent gene expression protects against excitotoxicity (Lee et al., 2005) and can act as a protective response to excitotoxic insults (Mabuchi et al., 2001). We found that basal levels of CREB (serine-133) phosphorylation (normalized to total CREB) were unaltered in GluN2B(CTR)/2A(CTR) neurons (118% ± 12% compared to GluN2B+/− neurons, p = 0.2). However we found that in response to treatment with NMDA C1, CREB (serine-133) phosphorylation was more prolonged in GluN2B(CTR)/2A(CTR) mice than in GluN2B+/− neurons, as assayed by western blot and immunohistochemistry (Figures 4A–4C), and also that activation of a CRE-reporter gene and the CREB target gene Adcyap1 was stronger in GluN2B(CTR)/2A(CTR) neurons than GluN2B+/− (Figures 4D and 4E). These differences did not extend to all transcriptional events: no differences were seen in the
Figure 4. The GluN2 CTD Subtype Influences Excitotoxicity by Differential Coupling to a CREB Shut-Off Pathway

(A) (Left) Quantitation of western blot analysis of phospho (serine-133)-CREB kinetics following NMDA	extsubscript{C1} treatment, normalized to total CREB (*p < 0.05; GluN2B	extsuperscript{+/+} n = 11; GluN2B	extsuperscript{2A(CTR)/2A(CTR)} n = 12). Mean ± SEM shown here and throughout the figure. (Right) Example blot (relevant samples within a single blot have been grouped).

(B) Quantitation of immunohistochemical analysis of phospho-CREB kinetics following NMDA	extsubscript{C1} treatment. (*p < 0.05; n = 7 (GluN2B	extsuperscript{+/+}); n = 4 (GluN2B	extsuperscript{2A(CTR)/2A(CTR)}); 200 cells analyzed in each condition, in each repeat.

(D–E) Quantitation of real-time RT-PCR analysis of Adenylnucleotide-mediated gene expression. (D) GluN2B levels, normalized to GAPDH (Mean ± SEM). (*p < 0.05; n = 3 (GluN2B	extsuperscript{+/+}); n = 2 (GluN2B	extsuperscript{2A(CTR)/2A(CTR)}). (E) CRE-mediated expression (Mean ± SEM) (*p < 0.05; n = 3 (GluN2B	extsuperscript{+/+}); n = 2 (GluN2B	extsuperscript{2A(CTR)/2A(CTR)}).
NMDC1-induced activation of Srxn1, an AP-1 target gene (Soriano et al., 2009), or suppression of the FOXO target gene Tnixp (Al-Mubarak et al., 2009; Figures S3A and S3B). To confirm whether CREB-dependent gene expression causally influenced vulnerability to NMDAR-mediated excitotoxicity we utilized the inhibitory CREB family member ICER which has previously confirmed effects on the induction of CRE-mediated gene expression when expressed in cortical neurons (Papadia et al., 2005). ICER expression increased levels of NMDC1-induced death in both GluN2B2A/2CTR/2A/CTR) and GluN2B2A/2A neurons (Figures 4F–4H). However, the effect of ICER on GluN2B2A/2A neurons was greater than its effect on GluN2B2A/2A neurons (Figure 4G), indicating that differential CREB activation is a contributing factor to the observed CTD subtype-dependent control of excitotoxicity.

One known regulator of CREB phosphorylation is nitric oxide (NO) which is produced when NMDAR-dependent Ca2+ influx activates nNOS, recruited to the NMDAR signaling complex via PSD-95 association with GluN2 subunits (Aarts et al., 2002). Whereas basal NOS activity can contribute to CREB phosphorylation in dentate granule cells (Ciani et al., 2002), it has been found to suppress CREB phosphorylation in the hippocampus (Park et al., 2004; Zhu et al., 2006). Furthermore, nNOS inhibition or deficiency boosts CREB phosphorylation following stroke (Luo et al., 2007). Compared to GluN2B2A/2A/2CTR/2A/CTR) neurons, GluN2B2A/2A neurons coupled more strongly to NMDC1-induced NO production (Figure 5A), despite nNOS and PSD-95 levels being the same (Figures S4A and S4B). Moreover, nNOS inhibition by 7-nitroindazole treatment enhanced CREB phosphorylation and CREB-dependent gene expression more strongly in GluN2B2A/2A neurons than GluN2B2A/2A/2CTR/2A/CTR) neurons, eliminating the CTD-subtype specific differences (Figures 5D–5F). This may be due to a stronger GluN2-PSD-95-nNOS coupling because association of GluN2B with PSD-95 was found to be stronger in P7 cortical extracts from GluN2A (three amino acid differences, GluN2B2A/2A/CTR/2A/CTR) mice (Figures 5B and 5C). Moreover, treatment of neurons with TAT-NR2B9c, which partly uncouples GluN2B from PSD-95 and NO production (Aarts et al., 2002), promoted more sustained CREB phosphorylation and enhanced CRE-reporter activity in NMDC1-treated GluN2B2A/2A neurons (Figures 5D–5F), but had little effect on these pathways in GluN2B2A/2A/2CTR/2A/CTR) neurons (with the caveat that TAT-NR2B9c disrupts GluN2B-PSD95 binding at lower concentrations than it does for GluN2A). Thus, CTD2B couples more strongly to PSD-95, NO production and nNOS-dependent CREB inactivation, enhancing vulnerability to excitotoxicity.

The basis for stronger association of PSD-95 with GluN2BWT compared to GluN2B2A/2A/2CTR/2A/CTR) could be due to different sequences immediately upstream of the conserved C-terminal PDZ ligand. We generated a chimeric variant of GluN2B in which the final 12 amino acids of its CTD have been replaced by those of GluN2A (three amino acid differences, GluN2B2A/2A/CTR/2A/CTR). Immunoprecipitation studies revealed that GluN2B2A/2A/CTR/2A/CTR) had a similar affinity for PSD-95 as GluN2B (Figure S4C), indicating that immediate upstream sequence differences are not the basis for differential association of PSD-95 with the CTDs of GluN2B and GluN2A. Recently, additional PSD-95 interaction domains have been discovered on internal regions of CTD2B (1086–1157; Cousins et al., 2009), which could contribute to the overall affinity of the CTD for PSD-95. The role of these additional regions in neurons is not yet clear, but could act to stabilize the primary interaction with the C-terminal PDZ ligand, or even act independently. Deletion of this region (creating GluN2B2A/2A/CTR/2A/CTR) resulted in a small reduction in PSD-95 association (Figure 5G). Importantly, NMDA-induced death following overexpression of GluN2B2A/2A/CTR/2A/CTR) in primary rat hippocampal neurons (as per the assays used in Figure 1) was significantly lower than in neurons overexpressing GluN2BWT (Figure 5H), even though whole-cell NMDAR currents were found to be the same in GluN2B2A/2A/CTR/2A/CTR) as wild-type GluN2BWT-expressing neurons (Figure 5I), implicating this region of the CTD in contributing to prodeath NMDAR signaling.

**DISCUSSION**

We have demonstrated distinct roles for the CTDs of GluN2B and GluN2A in determining the dose response of NMDAR-mediated excitotoxicity. CTD2B promotes neuronal death more efficiently than CTD2A, an effect which is observed regardless of whether the CTD is tethered to the channel portion of GluN2B or of
Moreover, this difference is observed both in the context of acute chimeric subunit expression in wild-type neurons, as well as in a knockin mouse where the CTD is swapped at the genetic level. Using the latter approach, we demonstrated the influence of the GluN2 CTD subtype in controlling excitotoxic lesion volume in vivo. We also show that the GluN2

Figure 5. The GluN2B CTD Couples More Strongly to a PSD-95-nNOS-Mediated CREB Shut-Off Pathway Than that of GluN2A

(A) DAF-FM-based NO assay (see Experimental Procedures) performed on neurons treated with NMDAC1 for 10 min. *p < 0.05; n = 6 (GluN2B+/+); n = 9 (GluN2B2A(CTR)/2A(CTR)). Mean ± SEM shown here and throughout the figure.

(B and C) GluN2BWT associates more strongly with PSD-95 than does GluN2B2A(CTR). GluN2B was immunoprecipitated from GluN2B+/+(WT) and GluN2B2A(CTR)/2A(CTR) (2AC) P7 cortical homogenates with a GluN2B N-terminal antibody. The presence of GluN2B and PSD-95 in the immunoprecipitate was analyzed by western blot, and the ratio of band intensities (PSD:GluN2B) was calculated (* p < 0.05; n = 11 (GluN2B+/+); n = 12 (GluN2B2A(CTR)/2A(CTR)).

(D and E) Western analysis of CREB phosphorylation (normalized to total CREB) in neurons pretreated as indicated with 7-nitroindazole (5 μM) or TAT-NR2B9c (2 μM) prior to NMDAC1 treatment for 5 or 30 min. *, p < 0.05; n = 10 (GluN2B+/+); n = 8 (GluN2B2A(CTR)/2A(CTR)). #, p < 0.05 t test comparison of the effect of the drug, compared to the (NMDA-treated) control.

(F) CRE reporter assay carried out as in Figure 4E. *p < 0.05; n = 5 (GluN2B+/+); n = 7 (GluN2B2A(CTR)/2A(CTR)). #, p < 0.05 paired t test comparison of the effect of the drug, compared to the control.

(G) Deletion of the GluN2B CTD between 1086–1157 lowers GluN2B affinity for PSD-95. HEK cells were transfected with plasmids encoding GluN1, PSD-95, and GluN2BWT or GluN2BD1086–1157. After 24 hr, protein was extracted, and the association of GluN2B or GluN2BD1086–1157 with PSD-95 was studied by coimmunoprecipitation, using an antibody to the N terminus of GluN2B. Upper, densitometric analysis of the resulting western blot (*, p < 0.05 paired t test; n = 6). Lower, an example blot.

(H) Deletion of the GluN2B CTD between 1086–1157 lowers GluN2B-mediated excitotoxicity. Neurons were transfected with the indicated GluN2B constructs or β-globin (plus eGFP marker), and NMDA-induced death was assessed as described in Figure 1D (*p < 0.05 paired t test [n = 8]; 250–300 cells analyzed per condition).

(I) Acute expression of GluN2BWT or GluN2B1086–1157 has a similar effect on NMDA-induced whole-cell currents. Neurons were transfected with the indicated constructs (plus eGFP marker), and whole-cell steady-state NMDAR-mediated currents evoked by 100 μM NMDA (normalized to cell capacitance) were compared to control-transfected neurons (β-globin; n = 4).

See also Figure S4.
The GluN2 CTD Subtype Controls Excitotoxicity

CTD subtype’s ability to influence excitotoxicity is overcome when strong excitotoxic insults are applied.

These findings raise the question as to whether subunit composition (and CTD identity) underlies the known differential prodeath signaling from synaptic versus extrasynaptic NMDARs, or whether it represents an additional factor that influences excitotoxicity (Hardingham and Bading, 2010). Although some studies have reported that GluN2B is enriched at extrasynaptic sites (Groc et al., 2006; Martel et al., 2009; Tovar and Westbrook, 1999), apparently in favor of the first alternative, on closer inspection this study, plus published work, favors the latter alternative. Ca²⁺ influx dependent on intense trans-synaptic activation of synaptic NMDARs is well tolerated and neuroprotective (Hardingham and Bading, 2010; Hardingham et al., 2002; Leveillé et al., 2010; Zhang et al., 2011). In contrast, similar Ca²⁺ loads induced by the chronic activation of extrasynaptic NMDARs couple preferentially to prodeath pathways (Dick and Bading, 2010; Dieterich et al., 2008; Hardingham and Bading, 2010; Hardingham et al., 2002; Ivanov et al., 2006; Leveillé et al., 2008; Wahl et al., 2009; Xu et al., 2009; Zhang et al., 2007).

At developmental stages where GluN2B-containing NMDARs dominate at all locations, differential synaptic versus extrasynaptic NMDAR signaling is still observed (Hardingham et al., 2002). Importantly, the strong trans-synaptic activation of synaptic GluN2B-containing NMDARs is neuroprotective (Martel et al., 2009; Papadia et al., 2008). Our current study shows that the identity of the GluN2 CTD profoundly influences excitotoxicity in the context of chronic activation of all (synaptic and extrasynaptic) NMDARs, scenarios that are likely to exist in pathological situations such as ischemia, traumatic brain injury, or glutamate dyshomeostasis triggered by disease-causing agents. Thus, location/stimulus-specific effects can be uncoupled from GluN2 subunit-specific effects, suggesting that subunit/CTD composition represents an additional factor that determines the level of excitotoxicity following chronic NMDAR activation. This is further supported by the fact that recent electrophysiological and immuno-EM studies have shown that GluN2 subunit composition may not be dramatically different at synaptic versus extrasynaptic sites (Harris and Pettit, 2007; Petralia et al., 2010; Thomas et al., 2006). Our observations that swapping CTD²B for CTD²A has little effect on whether a subunit ends up at a synaptic or extrasynaptic site is consistent with the aforementioned studies reporting that subunits do not have a strong location preference. Any apparent enrichment of synaptic sites for GluN2A may reflect the fact that GluN2A upregulation coincides developmentally with increased synaptogenesis (Liu et al., 2004), or be due to the influence of sequences outside of the CTD.

That notwithstanding, GluN2B has been reported to be partly enriched at extrasynaptic locations in neurons (Groc et al., 2006; Martel et al., 2009; Tovar and Westbrook, 1999), which suggests that GluN2 subtype effects and location effects may cooperate to exacerbate excitotoxicity under certain circumstances. Of note, recent work has revealed a causal role for enhanced GluN2B-containing extrasynaptic NMDARs in ischemic neuronal death (Tu et al., 2010). Also, a specific increase in GluN2B-containing NMDARs in medium-sized spiny striatal neurons, specifically at extrasynaptic locations, contributes to phenotype onset in a model of Huntington’s disease (Fan et al., 2007; Milnerwood et al., 2010), where the synaptic/extrasynaptic NMDAR balance controls mutant Huntington toxicity (Okamoto et al., 2009).

The idea that subunit composition influences excitotoxicity independently or additively to the influence of receptor location raises the possibility of a hierarchy of NMDARs when it comes to promoting excitotoxicity, based on the combination of composition (2A versus 2B) and location (synaptic versus extrasynaptic). Whereas strong activation of synaptic GluN2B-containing NMDARs is well-tolerated and neuroprotective (Martel et al., 2009; Papadia et al., 2008), the current study raises the possibility that activation of synaptic GluN2B-containing NMDARs (but not GluN2A-containing) could augment excitotoxicity in the context of chronic extrasynaptic NMDAR activation, for example, through enhanced NO production. This would explain the antixcitotoxic effect of TAT-NR2B9c, PSD-95 knockdown, or disrupting the PSD-95-nNOS interface (Aarts et al., 2002; Cao et al., 2005; Sattler et al., 1999; Soriano et al., 2008b; Zhou et al., 2010), and the reversal of CTD²B-dependent CREB inactivation by TAT-NR2B9c and nNOS inhibition (Figure 5). However, because PSD-95 clusters have been observed at extrasynaptic sites (Carpenter-Hyland and Chandler, 2006), colocalizing with extrasynaptic NMDARs (Petralia et al., 2010), the possibility that extrasynaptic CTD²B also contributes to this pathway should not be ruled out. Regardless of these issues, targeting GluN2B-PSD95 signaling to neurotoxic pathways offers genuine translational potential because it has been recently shown that stroke-induced damage and neurological deficits can be prevented in nonhuman primates by the administration of TAT-NR2B9c as late as 3 hr after stroke onset (Cook et al., 2012).

Investigations into why PSD-95 association with GluN2BWT is stronger than its association with GluN2B²A/²CTR implicated a previously identified internal region (Cousins et al., 2009) as a contributing factor, although deleting it had a relatively small effect on PSD-95 association, indicating that other determinants may also be relevant. Also, differing affinities of CTD²B and CTD²A for PSD-95 may be partly due to other factors binding CTD²A, occluding PSD-95 binding.

It is also possible that signals other than NO underlie the differential CTD subtype prodeath signaling, or that NO affects pathways other than CREB. One known NO target is the PI3K-Akt pathway, which is induced by NMDAR activity and neuroprotective in this context (Laforé-Cazal et al., 2002; Papadia et al., 2005). Modest NO levels promote PTEN S-nitrosylation, boosting Akt activity, whereas excessive NO also S-nitrosylates Akt itself, inactivating it (Numajiri et al., 2011). We have preliminary evidence that NMDA-induced Akt activation is enhanced in GluN2B²A/²CTR/²A/²CTR neurons (M.A. Martel and G.E. Hardingham, unpublished data), and it will be of interest to determine any role of differential NO production. Also, it would be of interest to know whether NMDAR signaling to protective transcriptional responses other than CREB are sensitive to GluN2 CTD subtype (e.g., Iduna; Andrabí et al., 2011). These, and other issues surrounding subunit-specific signaling could benefit from a future systematic analysis of the NMDAR
signaling complex in GluN2B+/+ versus GluN2B2A(CTR)/2A(CTR) neurons.

EXPERIMENTAL PROCEDURES

Neuronal Culture and Induction of Excitotoxicity
Cortical mouse and hippocampal rat neurons were cultured as described (Papadia et al., 2008) at a density of between 9 and 13 × 10⁶ neurons per cm² from E17.5 mice or E21 rats with neurobasal growth medium supplemented with B27 (Invitrogen, Paisley, UK). Stimulations of cultured neurons were done in most cases after a culturing period of 9–11 days, during which neurons develop a network of processes, express functional NMDA-type and AMPA/kainate-type glutamate receptors, and form synaptic contacts. Other experiments were performed at DIV 18. To apply an excitotoxic insult, neurons were first placed overnight into a minimal-defined medium (Papadia et al., 2005) containing 10% MEM (Invitrogen) and 90% salt-glucose-glycine (SGG) medium (Bading et al., 1993; SGG: 114 mM NaCl, 0.219% NaHCO₃, 5.292 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, 1 mM Glycine, 30 mM Glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolality 325 mosm/l; Papadia et al., 2005). Neurons were then treated with NMDA (Tocris Bioscience, Bristol, UK) at the indicated concentrations for 1 hr, after which NMDARs were blocked by adding the antagonist MK-801 (10 μM). After a further 23 hr, neurons were fixed and subjected to DAPI staining, and cell death was quantified by counting (blind) the number of shrunken, pyknotic nuclei as a percentage of the total. For analysis of excitotoxicity in GluN2B+/+ versus GluN2B2A(CTR)/2A(CTR) neurons, approximately 800–1,200 cells were analyzed per condition, per replica (repeated across several replicates).

GluN2B-2A(CTR) Knockin Mouse
GluN2B-2A(CTR) knockin mice contain a GluN2B gene in which the protein coding portion of the C-terminal exon has been replaced with the protein coding region of the C-terminal exon of GluN2A (C-terminal domain replacement, CTR). The C-terminal exon encodes amino acids 867G to 1482V (GluN2B) and 866G to 1464V (GluN2A), which represents over 95% of the CTD, beginning at position 838E (GluN2A) and 839E (GluN2B). All other regions of the GluN2B gene are unaltered, including the 3' UTR, although there remains a 61 bp insert containing a loxP site located after the STOP codon at the beginning of the 3'UTR (a remnant of the excision of the Neo-selection cassette). To obtain cultured neurons from GluN2B2A(CTR)/2A(CTR) mice, male and female heterozygous GluN2B+/2A(CTR) mice were mated, and the cortices from individual E17.5 mice were cultured as above. See Supplemental Experimental Procedures for further details.

Transfection and Following the Fate of Transfected Cells
Neurons were transfected at DIV8 using Lipofectamine 2000 (Invitrogen), using an established protocol (McKenzie et al., 2005). Transfection efficiency was approximately 5%. Greater than 99% of eGFP-expressing transfected neurons were NeuN-positive, and <1% were GFAP-positive (Soriano et al., 1999). Greater than 99% of eGFP-expressing transfected cells. Coexpression at this ratio was confirmed in the case of pRFP (Papadia et al., 2005) containing 10% MEM (Invitrogen) and 90% salt-glucose-glycine (SGG) medium (Bading et al., 1993; SGG: 114 mM NaCl, 0.219% NaHCO₃, 5.292 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, 1 mM Glycine, 30 mM Glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolality 325 mosm/l; Papadia et al., 2005). Neurons were then treated with NMDA (Tocris Bioscience, Bristol, UK) at the indicated concentrations for 1 hr, after which NMDARs were blocked by adding the antagonist MK-801 (10 μM). After a further 23 hr, neurons were fixed and subjected to DAPI staining, and cell death was quantified by counting (blind) the number of shrunken, pyknotic nuclei as a percentage of the total. For analysis of excitotoxicity in GluN2B+/+ versus GluN2B2A(CTR)/2A(CTR) neurons, approximately 800–1,200 cells were analyzed per condition, per replica (repeated across several replicates).

Analysis of Extrasynaptic NMDAR Currents
To measure extrasynaptic NMDAR currents, synaptically located NMDARs were blocked by quanta activation-mediated blockade by MK-801, as previously described (Markert et al., 2009; Papadia et al., 2008). Briefly, whole-cell NMDAR currents were recorded (100 μM NMDA, in Mg²⁺-free and TTX/PTX-containing recording solution), after which the agonist was washed-out the recording chamber for 2 min. Irreversible NMDAR open-channel blocker MK-801 (10 μM; Tocris Bioscience) was then applied for 10 min, effectively antagonizing NMDARs located at the synapse and experiencing the localized, quantal presynaptic glutamate release (Markert et al., 2009; Nakayama et al., 2005). Following the 10 min incubation period, MK-801 was then washed out (2 min), and the resulting extrasynaptic NMDAR currents were acquired.

Other Procedures
See Supplemental Experimental Procedures for details of genotyping, plasmid generation, electrophysiological recording conditions, qPCR analysis, Ca²⁺ imaging, stereotaxic NMDA administration, NO assays, western blotting and immunofluorescence, co-immunoprecipitation, and equipment settings. All procedures were authorized under a UK Home Office approved project licence and adhered to regulations specified in the Animals (Scientific Procedures) Act (1986) and approved by the University of Edinburgh’s Local Ethical Review Committee. Statistical testing involved a 2-tailed paired Student’s t test. For studies employing multiple testing, we used a one-way ANOVA followed by Fisher’s LSD or Tukey’s post hoc test.

SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/j.neuron.2012.03.021.

ACKNOWLEDGMENTS
We thank Anne Stephenson and Paolo Sassone-Corsi for plasmids. G.E.H. is funded by a Medical Research Council Senior Research Fellowship, and this work is funded by the Wellcome Trust, MRC, the BBSRC, the Alzheimer’s Society, and EU ITN grant NPLAST (Nr 289581). S.G.N., T.J.R., N.H.K. were supported by the Genes to Cognition Program funded by the Wellcome Trust and EU grants (Projects GENOCODYS Nr 241995, EUROSPI No. 242498, and SYNSYS No. 242167). P.C.K. is supported by the MRC. T.J.R. is supported by a Wellcome Trust Sanger Institute for support.

Accepted: March 1, 2012
Published: May 9, 2012

REFERENCES


